Original Report

Long-term community-based results of breast-conserving therapy in early-stage breast cancer


 

Background Multicenter clinical trials conducted primarily at academic centers have shown that breast-conserving therapy (BCT) and mastectomy lead to equivalent overall survival (OS) for women with early-stage breast cancer.

Objective To determine rates of BCT and OS after conservation therapy in a large urban community practice, compare them with national rates, and identify risk factors for survival.

Methods We identified 1,172 T1-2, N0 breast cancer patients diagnosed during 1997-2007 in our hospital tumor registry and compared the rates of BCT and adjuvant radiotherapy with a similar population in the SEER [Surveillance, Epidemiology, and End Results] database (N = 232,898) for the same treatment period. Cox proportional hazards models were used to assess the influence of age at diagnosis, tumor grade, biomarker status, margin status, and receipt of hormones, radiation, or chemotherapy on OS after BCT.

Results The rate of breast-conserving surgery (BCS) was higher in our practice compared with the national average (90.9% and 66.4%, respectively). The rate of adjuvant radiation after BCS in our practice was 93.7%; survival estimates were higher for patients treated with adjuvant radiation across all age groups, compared with the national estimates (92.5% and 72.9%). Younger age and receipt of radiation were associated with improved survival.

Limitations Retrospective study design; confounding factors such as comorbidities were not considered.

Conclusions We had high rates of BCT and adjuvant radiation in early-stage breast cancer patients in our community practice, which resulted in excellent survival rates that compared favorably with those in large academic centers and emphasizes the role of appropriate use of adjuvant radiation.

Funding Vantage Oncology

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

VIDEO: Doctors should be challenged to extend AIs
MDedge Hematology and Oncology
VIDEO: Direct-to-patient study empowers patients, accelerates research
MDedge Hematology and Oncology
Liquid biopsies prove useful alternative to tissue biopsies
MDedge Hematology and Oncology
MyPathway: Targeted therapies show promise in nonindicated tumors
MDedge Hematology and Oncology
VIDEO: Dr. William A. Gradishar and Dr. Hope S. Rugo discuss #ASCO16
MDedge Hematology and Oncology
Adjuvant AI therapy for breast cancer: 10 years is superior to 5 years
MDedge Hematology and Oncology
Immune agonist, checkpoint inhibitor combo shows good tolerability
MDedge Hematology and Oncology
In-person, telephone genetic counseling yield similar outcomes
MDedge Hematology and Oncology
FDA reports shortage of doxorubicin for injection, initiates importation
MDedge Hematology and Oncology
Point/Counterpoint: Should breast MRI be used routinely in the preoperative evaluation of breast cancer?
MDedge Hematology and Oncology